WO2025109387 - GLP-1R AGONIST AND THERAPEUTIC METHOD THEREOF
National phase entry is expected:
Publication Number
WO/2025/109387
Publication Date
30.05.2025
International Application No.
PCT/IB2024/058943
International Filing Date
13.09.2024
Title **
[English]
GLP-1R AGONIST AND THERAPEUTIC METHOD THEREOF
[French]
AGONISTE DE GLP-1R ET SON PROCÉDÉ THÉRAPEUTIQUE
Applicants **
ASCLETIS PHARMA (CHINA) CO., LIMITED
Inventors
LIANG, Bin
WU, Jinzi Jason
YANG, Bailing
Priority Data
202311582240.2
24.11.2023
CN
63/603,854
29.11.2023
US
202311686034.6
08.12.2023
CN
202410142451.2
31.01.2024
CN
202410202078.5
22.02.2024
CN
202410398964.X
02.04.2024
CN
202410584679.7
11.05.2024
CN
202410906296.7
05.07.2024
CN
63/673,461
19.07.2024
US
202411237013.0
04.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3219 | |
| EPO | Filing, Examination, Granting | 13259 | |
| Japan | Filing, Examination, Granting | 2339 | |
| South Korea | Filing, Examination, Granting | 2736 | |
| USA | Filing, Examination, Granting | 10190 |
Total:
31,743
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure describes GLP-1R modulating the compounds of Formula (I) that are useful for treating GLP-1R-mediated diseases or conditions.[French]
La présente invention concerne des GLP-1R modulant les composés de formule (I) qui sont utiles pour traiter des maladies ou des états à médiation par GLP-1R.